<DOC>
	<DOCNO>NCT00004387</DOCNO>
	<brief_summary>OBJECTIVES : I . Determine effectiveness fetal nigral transplantation patient Parkinson 's disease .</brief_summary>
	<brief_title>Phase II Double Blind Controlled Trial Nigral Grafting Patients With Parkinson 's Disease</brief_title>
	<detailed_description>PROTOCOL OUTLINE : This placebo control , randomize , double blind study . Patients randomly assign 1 3 treatment group . All patient receive 2 separate operation substantia nigra either 4 fetus ( Group A ) 1 fetus ( Group C ) implant striatum side . Group B patient receive 2 separate placebo operation without fetal transplantation . The second surgical procedure begin approximately 1 week first operation . After 2 year , treatment compare . If transplant show benefit Parkinson 's disease , patient receive placebo operation offer transplant surgery final year study .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA : Disease Characteristics Advanced Parkinson 's disease HoehnYahr stage IV worse `` '' period HoehnYahr stage III well `` '' period Predictable motor fluctuation least 20 % waking day `` '' stage No atypical parkinsonism secondary parkinsonism Prior/Concurrent Therapy Biologic therapy : Not specify Chemotherapy : Stable dos levodopa/carbidopa antiparkinson therapy 2 month prior study Surgery : No previous intracranial/neurosurgical procedure Patient Characteristics Renal : Creatinine clearance least 70 mL/min creatinine great 1.8 mg/dL Protein great 300 mg/dL Other : Not pregnant nursing Adequate contraception require fertile patient Prior history good response levodopa No sensitivity cyclosporine Not HIV positive ( e.g. , HIV I II ) No human Tcell leukemia/lymphoma virus ( HTLV1 ) No tremor interfere stereotactic surgery No clinically significant medical , neoplastic infectious disease No clinically significant laboratory abnormality No dementia precludes sign informed consent score le 24 MiniMental status examination</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2000</verification_date>
	<keyword>Parkinson disease</keyword>
	<keyword>neurologic psychiatric disorder</keyword>
	<keyword>rare disease</keyword>
</DOC>